2. Academic Validation
  3. New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 2: Synthesis and structure-activity relationships in the S-3578 series

New broad-spectrum parenteral cephalosporins exhibiting potent activity against both methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Part 2: Synthesis and structure-activity relationships in the S-3578 series

  • Bioorg Med Chem. 2004 Aug 1;12(15):4211-9. doi: 10.1016/j.bmc.2004.05.022.
Hidenori Yoshizawa 1,  Tadatoshi Kubota,  Hikaru Itani,  Hiroyuki Ishitobi,  Hideaki Miwa,  Yasuhiro Nishitani
Affiliations

Affiliation

  • 1 Shionogi Research Laboratories, Shionogi & Co. Ltd, 12-4, Sagisu 5-chome, Fukushima-ku, Osaka 553-0002, Japan. hidenori.yoshizawa@shionogi.co.jp
PMID: 15246097 DOI: 10.1016/j.bmc.2004.05.022
Abstract

Among the prepared novel cephalosporin derivatives related to S-3578, a series of 7beta-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(Z)-ethoxyiminoacetamido]-3-[1-(aminoalkyl)-1H-pyrazolo[4,3-b]pyridinium-4-yl]methyl-3-cephem-4-carboxylate showed potent activity against both MRSA and Pseudomonas aeruginosa, and displayed good water solubility.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z